Norway delivered the following statement on non-violation and situation complaints at the June 2015 meeting of the WTO TRIPS Council.
TRIPS COUNCIL MEETING 9 AND 10 JUNE 2015
6. NON-VIOLATION AND SITUATION COMPLAINTS
Statement by Norway
- We would like to join the overwhelming majority of members that have intervened today.
TRIPS Council June 2015: Norway provides unequivocal support of LDC Group request for extension of the transition periodSubmitted by thiru on 17. June 2015 - 9:31
On Wednesday, 10 June 2015, Norway - a high-income member of the WTO with a GDP per capita of 100,898 USD- (Source: World Bank, 2013) delivered this powerful intervention supporting the LDC Group request for an extension of the transition period for pharmaceutical products. On the LDC Group's specific request on extension until graduation, Norway said,
WTO TRIPS Council (June 2015): India underscores the importance of de-linkage in discussions of financing innovationSubmitted by thiru on 10. June 2015 - 15:42
In discussions at the June 2015 WTO TRIPS Council on the role of intellectual property in financing innovation, India underscored its commitment to the principle of de-linkage by stating,
Innovation should not be viewed within the narrow prism of intellectual property monopolies but framed within a holistic, knowledge ecosystem that includes open innovation, open knowledge approaches and de-linkage of R&D costs from product prices
On Tuesday, 9 June 2015, India delivered the following statement on Non-Violation and Situational Complaints (IP/C/W/385/Rev 1). Brazil introduced the paper along with 16 other WTO members including India. The 17 co-sponsors of this paper include Argentina, Plurinational State of Bolivia, Brazil, China, Colombia, Cuba, Ecuador, Egypt, India, Indonesia, Kenya, Malaysia, Pakistan, Peru, Russian Federation, Sri Lanka and Bolivarian Republic of Venezuela.
The joint submission proposes the following action item for the Nairobi Ministerial from 15 December 2015 to 18 December 2015:
WTO TRIPS Council (June 2015): LDC Group Presentation on the Extension of the Decision on Pharmaceutical ProductsSubmitted by thiru on 10. June 2015 - 8:54
The LDC Group delivered the following statement on Wednesday, 8 June 2015 during WTO TRIPS Council discussions on their request on the extension of the decision on pharmaceutical products.
PRESENTATION BY THE LDCS GROUP TO THE TRIPS COUNCIL ON THE EXTENSION OF THE DECISION ON PHARMACEUTICAL PRODUCTS, 09-10 JUNE 2015
I make this presentation on behalf of the LDCs group. We thank you for calling this meeting and for your report.
WTO TRIPS Council: World Health Organization issues unequivocal support of LDC transition period for pharmaceutical productsSubmitted by thiru on 10. June 2015 - 5:15
Today, on Wednesday, 10 June 2015, the World Trade Organization's TRIPS Council discussed the LDC Group's Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement (Source: IP/C/W/605).
WTO TRIPS Council (February 2015): EU statement on LDC extension of transition period for pharmaceutical productsSubmitted by thiru on 3. June 2015 - 4:25
The following statement was delivered by the European Union at the February 2015 session in response to the proposal by the LDC Group Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement.
In particular, the European Union noted,
June 2015: WTO reports on India's Section 3(d) and compulsory licensing provisions - WTO Trade Policy Review - IndiaSubmitted by thiru on 2. June 2015 - 7:29
On 2 June 2015 and 4 June 2015, the World Trade Organization (WTO) is conducting a trade policy review of India. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the "Trade Policy Review Body which is actually the WTO General Council — comprising the WTO’s full membership — operating under special rules and procedures" (Source: WTO, Trade Policy Reviews: Brief Introduction).
WHA68: Statement of HAI/KEI on Follow-up to 2014 HLM on comprehensive review + assessment of prevention and control of NCDsSubmitted by thiru on 26. May 2015 - 2:22
On Tuesday, 26 May 2015, the following statement was delivered in Committee B of the 68th World Health Assembly on behalf of Stichting Health Action International and Knowledge Ecology International on the topic: Follow-up to the 2014 high-level meeting of the United Nations General Assembly to undertake a comprehensive review and assessment of the progress achieved in the prevention and control of noncommunicable diseases.
May 21, 2015- Agenda for KEI/KEI Europe panel on Compulsory licensing of patents on drugs, vaccines and diagnostic testsSubmitted by thiru on 20. May 2015 - 9:36
Compulsory licensing of patents on drugs, vaccines and diagnostic tests
Knowledge Ecology International (KEI) and Knowledge Ecology International Europe (KEI Europe):
DATE: Thursday, 21 May 2015
VENUE: Kofi Annan Room, UNAIDS, Avenue Appia 20
- Ellen 't Hoen, Medicines, Law and Policy
WHA68: Greek Minister of Health - Panagiotis Kouroumplis - calls for de-linkage of R&D from the price of health technologiesSubmitted by thiru on 18. May 2015 - 16:15
On Monday, 18 May 2015, the Greek Minister of Health, Panagiotis Kouroumplis, delivered the following speech at the World Health Assembly in Geneva, explicitly calling for the de-linkage of the "cost of R&D from the final price of medicines" while highlighting the deleterious effects of austerity measures eroding public health systems, counter to the theme of WHA68, "Resilient Health Systems".
Here is his speech in full:
Madam Director General, dear colleagues, excellencies, ladies and gentlemen
WHO Expert Committtee adds trastuzumab, imatinib, daclatasvir, sofosbuvir, bedaquiline and delaminid to EMLSubmitted by thiru on 8. May 2015 - 2:34
On Friday, 8 May 2015, the World Health Organization (WHO) unveiled its 19th WHO Model of Essential Medicines (April 2015).
With respect to cancer drugs (Section 8.2, Cytoxic and Adjuvant Medicines), the Executive Summary noted that the Committee added 16 new medicines.
WHO donors in 2014 (US, Gates Foundation, UK, GAVI and Canada): Setting the agenda for global public health?Submitted by thiru on 7. May 2015 - 4:46
In preparation for the 68th World Health Assembly, to be convened in Geneva from 18 May 2015 to 26 May 2015, the World Health Organization (WHO) prepared a document (A68/INF./1, 1 May 2015), entitled "Annex to the Financial Report for the year ended 31 December 2014, Voluntary contributions by fund and by contributor).
WIPO CDIP 15: Statement of Brazil on evaluation of the Project on Open Collaborative Projects and IP-Based ModelsSubmitted by thiru on 21. April 2015 - 4:00
On Tuesday, 21 April 2015, the 15th session of the World Intellectual Property Organization's (WIPO) Committee on Development and Intellectual Property (CDIP) considered the Evaluation Report for the Project on Open Collaborative Projects and IP-Based Models (CDIP/15/3). This project on open collaborate development models is based on Recommendation 36 of the WIPO which states,
Knowledge Ecology International (KEI) will present the following statement on 20 April 2015 to the Open Session of the 20th Expert Committee on the Selection and Use of Essential Medicines.
Statement of Knowledge Ecology International: WHO 20th Expert Committee on the Selection and Use of Essential Medicines, with specific focus on expanding access to new cancer drugs, when available at affordable prices
20 April 2015
Dear members of the WHO Expert Committee and the WHO secretariat,